Chesapeake IRB Announces Acquisition of MaGil IRB
Columbia, MD (June 9, 2017) – Chesapeake IRB (“Chesapeake”), the leading technology-enabled independent institutional review board (“IRB”) serving the clinical research industry, announced it has acquired MaGil IRB (“MaGil”), a central IRB located in Rockville, MD.
The MaGil acquisition provides Chesapeake with additional AAHRPP accredited review capacity and a talented staff that further broadens Chesapeake’s presence in CROs, pharmaceutical companies, and biotech companies. This marks Chesapeake’s fifth acquisition of an AAHRPP accredited IRB since 2013, further positioning itself as the best IRB to support the growth in the clinical research industry.
“Today we are delighted to welcome MaGil IRB to the Chesapeake family,” said Jeff Wendel, President and CEO of Chesapeake. “Together, we are even better positioned to deliver unparalleled human subject protections and oversight and exceptional client service.”
“Joining with Chesapeake allows MaGil customers to benefit from Chesapeake’s innovative cloud-based IRB platform, CIRBI, while continuing the joint mission of safeguarding the rights and welfare of clinical research participants,” said Gil Price, founder and CEO of MaGil IRB.
Chesapeake IRB is a portfolio company of Linden Capital Partners.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit www.chesapeakeirb.com for more information.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.